Delisting risk
Polyrizon (PLRZ)
Develops NASARIX and intranasal hydrogel drug-delivery platforms.
$12.50
Pre-market−0.25 (−1.96%)
At close$12.75(−11.21%)
In millions of USD, except per-share figures
| In millions | Q2 FY22Jun 2022 | Q4 FY22Dec 2022 | Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | — | 0 | — | 1 | — | — | 2 | 4 | |
| Research & development | 0 | 0 | 0 | 0 | — | 0 | — | 0 | 0 | 0 | 1 | 1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 1 | 2 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 1 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −1 | 0 | 0 | 0 | — | 0 | — | — | — | — | −2 | −4 |
| 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 2 | 1 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | 0 | 0 | 0 | 0 | −1 | — | — | — | — | 0 | −3 |
| Net income from continuing operations | −1 | 0 | 0 | 0 | 0 | −1 | — | −1 | — | — | 0 | −3 |
| Net income | −1 | 0 | 0 | 0 | 0 | −1 | — | −1 | — | — | 0 | −3 |
| EPS, basic | $0.00 | −$0.04 | $0.00 | $0.00 | −$29.95 | −$29.95 | −$36.30 | −$36.30 | −$0.06 | −$0.06 | −$1.41 | −$1.96 |
| EPS, diluted | $0.00 | −$0.04 | $0.00 | $0.00 | −$29.95 | −$29.95 | −$36.30 | −$36.30 | −$0.06 | −$0.06 | −$1.41 | −$1.96 |
| Weighted average shares, basic | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 |
| Weighted average shares, diluted | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 |
| EBITDA | −1 | 0 | 0 | 0 | — | 0 | 0 | −1 | 0 | 0 | −2 | −4 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | — | — | 0 | 0 |
| EBIT | −1 | 0 | 0 | 0 | — | 0 | — | −1 | — | — | −2 | −4 |